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Introduction
Nonselective toxicity is a major factor that contributes to poor prognosis for cancer patients. One of the approaches to improve therapeutic effectiveness and decrease systemic side effects is design of targeted anticancer prodrugs for tumor site-specific activation [1] . A number of prodrug designs have been proposed to meet these requirements by taking advantages of low extracellular pH [2] , elevated enzymes in tumor tissues [3] , hypoxic environment inside the tumors [4] , and so on [5] . Hypoxia is a common feature of most solid tumors, tissue hypoxia due to inadequate blood supply and rapid tumor growth will induce cancer cells resistant to radiotherapy and to many chemotherapeutic strategies [6] . However, tumor hypoxia also distinguishes tumor cells from normal cells, thus providing a unique strategy for selective cancer therapy [7] . Hypoxic cells prevalent in solid tumors could be selectively targeted by bio-reductive compounds whose activation is limited to hypoxic tumor regions thus minimizing the systemic side effects [8] . Hypoxia-activated prodrugs are activated by biotransformation following reductive metabolism by endogenous human cellular oxidoreductases [9] .
Although a variety of oxidoreductases are known to be involved in prodrug M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT reduction, two-electron oxidoreductases NAD(P)H:quinone oxidoreductase (NQO1)
is shown to be the most extensively researched [10] . NQO1 (E.C. 1.6.99.2, reduced nicotinamide adenine dinucleotide phosphate, also known as DT-diaphorase, DTD) is an obligate two electron quinone reductase. This flavoenzyme can utilize either NADH or NADPH to catalyze the reduction of various bio-reductive prodrugs [11] .
NQO1 has received considerable attention in recent years for prodrug development, due to the fact that this enzyme is overexpressed in various types of tumors as compared with the paired normal tissue, making it an interesting target enzyme.
Elevated levels of NQO1 in human tissues have been observed in primary tumors from lung (12-to 18-fold), liver (4-to 19-fold), colon (3-to 4-fold), and breast (3-fold)
compared with normal tissue [12] . Therefore, NQO1 becomes an attractive target for enzyme-directed anticancer prodrugs designed for reductive activation.
Several classes of bio-reductive compounds that can undergo enzymatic reduction to active species have been developed [13] [14] [15] . Quinone is the structural moiety commonly associated with reductive activation which can be easily reduced by various reductive enzymes to hydroquinones [16] . Quinone is present in many bio-reductive compounds, such as mitomycin C (1), a clinically used antitumor antibiotic [17] , and EO9 (2) that shows improved properties over mitomycin C [18] , as well as other quinone-containing compounds ( Figure 1 ) [19] [20] . The indolequinone nucleus is the most common quinone which is a good substrate of NQO1 and can be activated through an obligate and non-reversible two-electron reduction. Recently, structure-activity relationship (SAR) analysis of the M A N U S C R I P T
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indolequinone moiety and the molecular features relating to substrate specificity for human NQO1 has been examined [21] [22] [23] . Evidence indicates that substitution with a potential leaving group at the 3-position of the indolequinone moiety is a viable means for bio-reductive drug delivery [24] . Figure 2 shows a proposed mechanism for the release of drugs following reduction of the indolequinone prodrug 5. When 5 is reduced by two electrons to dihydroxyindole 6 in the presence of NQO1, the electron-density at the indole nitrogen increases markedly, triggering expulsion of the leaving group 7. This expulsion generates an alkenyliminium electrophile 8, which is a potential electrophile capable of DNA-alkylation or other cellular-damaging events contributing to the cytotoxicity to tumor cells [25] . This reduction is often inhibited in the presence of oxygen, thus increasing the specificity for hypoxic solid tumors.
Interestingly, if the leaving group 7 is a bioactive group, thus they may have secondary biological effects due to the eliminated molecule 7 [26] [27] [28] . As shown in Figure 2 , there are two mechanisms through which indolequinone-based prodrugs can induce cytotoxicity. Firstly, the indolequinone structure itself can be converted to a reactive, cytotoxic species by reduction to a hydroquinone. Secondly, the indolequinone moiety can be used to form a prodrug that selectively releases other cytotoxic agents to hypoxic tissues. Thus, design and synthesis of NQO1-activated indolequinone prodrugs by functionalization at the (indol-3-yl)methyl position with a variety of cytotoxic leaving groups have become an interesting area to develop targeted anticancer prodrugs. Natural product oridonin (10), an ent-kaurene diterpenoid extracted from Radosia Rubescens, was firstly identified in 1967 as an antitumor agent [29] [30] . Numerous researches have shown that oridonin has certain antitumor effects on human breast cancer, gallbladder cancer, leukemia, gastric cancer, human cervical carcinoma, hepatocellular carcinoma and other tumors [31] . In our previous studies, oridonin and its semi-synthesized analogues exhibited safe, unique, and extensive antitumor activities [32] [33] [34] . In the present study, a series of reductively triggered novel prodrugs were designed by substitution at the 3-position of the indolequinone nucleus with cytotoxic diterpenoids oridonin or its analogues. The active drug oridonin or its analogues were subsquently released under bio-reductive transformation by NQO1 which is overexpressed in tumor tissues. This design is expected to enhance drug specificity toward tumor cells and thus reduce side effects.
Herein, we report the design, synthesis and preliminary drug release study of NQO1-targeted oridonin prodrugs possessing indolequinone moiety for bio-reductively triggered drug release. 
Results and discussion
Synthesis of NQO1-targeted oridonin prodrugs
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Effect of prodrugs on cancer cell growth
To assess the extent to which NQO1 contributes to the cytotoxicity of these Consequently we measured the antiproliferative activities of three potent representative compounds 29f, 29h, 29n in the presence of dicoumarol (DIC, 10 mM), an effective NQO1 inhibitor that blocks the catalytic efficiency of the enzyme by interacting with the NAD(P)H-binding site of the oxidized enzyme form. As shown in Figure 3A , the co-incubation with DIC led to lower sensitivity of A549 cells to compounds 29f, 29h, 29n, and increasing IC 50 values up to 7.5-, 4.5-and 5.9-fold, respectively, which implies that they might be partially influenced by their NQO1-catalyzed bio-reductive activation.
Furthermore, we found the synergic effect of compound 29h in both A549 and H596 cells. As shown in Figure 3B , compound 29h contains an oridonin analogue (compound 13) and indolequinone (27) MTT methods, cells were incubated with indicated compounds for 72h, (means ± SD, n=3).
Compound 29h is a good substrate of NQO1
To assess the efficacy of these newly synthesized compounds as substrates for NQO1, HPLC analysis was used to monitor the decomposition of 29h in the presence or absence of NQO1 in pH 7.4 buffer. Upon reduction with NQO1, the electron M A N U S C R I P T
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density at the indole nitrogen increases drastically, triggering expulsion of the leaving group in a reverse-Michael-like process, releasing the drug at the 3-position of the indolequinone nuclear. As shown in Figure 4 , within 40 min, a significant amount of 29h was decomposed in the presence of NQO1, and in 12 h, nearly 70% of the compound was consumed. However, during the same time period, in the absence of NQO1, 29h remained stable in pH 7.4 buffer suggesting NQO1 could mediate hypoxic induced, enzyme-directed bio-reductive drug delivery.
Moreover, docking study of representative compound 29h was further performed to observe whether this prodrug is a good substrate of NQO1. The molecular operating environment (MOE) was used to analyse the binding mode of 29h with NQO1, Figure   4B showed the possible docking conformation for 29h with NQO1. It can be clearly seen that indolequinone moiety binds with the residues of the NQO1 active site and flavin adenine dinucleotide (FAD) which is required for NQO1 catalytic activity 
Compound 29h induces NQO1 dependent apoptotic cell death
To further investigate the effect of 29h on cell proliferation, Hoechst 33342 staining was used to assess 29h-dependent changes in cell morphology. h, cells were then collected and stained with JC-1, followed by flow cytometric analysis.
Compound 29h induces cell cycle arrest at G2/M phase
Most of the antitumor agents inhibit cell proliferation through induction of cell cycle arrest [37] . To determine whether the suppression of the cell growth by 29h was caused by a cell-cycle effect, DNA-based cell cycle analysis was performed using flow cytometry. As illustrated in Figure 7 , compound 29h influenced cell cycle progression at sub-micromolar concentrations and caused blockage of the cell cycle at M A N U S C R I P T 
A C C E P T E D ACCEPTED MANUSCRIPT
Compound 29h regulates apoptotic related proteins
The intrinsic and extrinsic pathways that lead to the induction of apoptosis are known to activate a series of proteases known as caspases [38] . To explore the signalling mechanism of 29h-induced apoptosis, we examined the expression of the apoptosis-related proteins including caspase-3, -8, -9, and cytochrome C. As shown in Figure 8A , A549 cells treated with 29h had increased levels of the cleaved active forms of caspase-3, -8, -9, and cytochrome C in a dose-dependent manner, indicating M A N U S C R I P T
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that 29h activated the caspase cascade.
The Bcl-2 family has been identified as essential proteins in controlling the mitochondrial pathway. This family includes pro-apoptotic proteins (e.g., Bax, Bad) and anti-apoptotic proteins (e.g., Bcl-2, Bcl-xL), the balance between these two groups determines the fate of cells [39] . Bax can act on the mitochondria to induce the mitochondrial permeability transition, resulting in the release of some components, including cytochrome C. To confirm whether such a mechanism is involved in apoptosis induced by 29h, the expression of Bax and Bcl-xl was examined by Western
Blotting analysis. As shown in Figure 8B , the expression of Bax in A549 cells began to increase after the treatment of 29h with increasing concentrations for 48 h, while the Bcl-xl expression markedly decreased at concentrations of 0.25 µM and above.
While a similar trend was observed in H596 cells, however, such effect was minimal. were determined by Western Blotting using specific antibodies, β-actin was used as internal control.
In vivo antitumor activity of compound 29h
To evaluate the in vivo antitumor activity of 29h, liver cancer xenograft in mice was established by subcutaneous inoculation of H22 cells into the right flank of mice.
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As shown in Figure 9A , compound 29h caused a remarkable reduction in tumor growth, and reached a 64.3% reduction by the end of the observation period compared with administration of vehicle only. It is interesting to note that the effect on tumor volume reduction by 29h was much better than that of oridonin, which caused a 50.8%
of reduction at day 18. During the whole treatment period, no significant weight changes in the treated animals were observed ( Figure 9D ), suggesting that 29h has minimal toxicity. 
Conclusion
In this study, a series of hypoxia-selective prodrugs were designed and synthesized Overall, these NQO1-targeted oridonin prodrugs possessing indolequinone moiety represent a promising class of cytotoxic agents with potential novel therapeutic values.
All properties including the cancer cell selectivity, potency, and promising in vivo activity of compound 29h suggested its outstanding potential as a personalized anticancer therapy [40] . 
Experimental section
Materials
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT),
Cell Lines and Cell Culture
Human NSCLC cell lines A549 (NQO1+), NCI-H596 (NQO1-) and Human colon carcinoma cells HT-29 (NQO1+) were obtained from the American Type Culture Collection (ATCC, USA). Cells were grown in RPMI 1640 medium (Life Technologies, USA). The media for all cell lines were supplemented with 10% fetal bovine serum (Life Technologies, USA), 100 µg/mL streptomycin (Life Technologies, USA), and 100 U/mL penicillin (Life Technologies, USA) and maintained at 37°C in a humidified atmosphere with 5% CO 2 .
Determination of In Vitro Anticancer Activity
The overall growth level of human cancer cell lines was determined by the MTT colorimetric assay. Cells were plated in 96-well plates at a density of 10000 cells/mL and incubated at 37 °C in a humidified 5 % CO 2 incubator for 24 h prior to the experiments. After medium removal, 100 µL of fresh medium containing the test compound at different concentrations was added to each well and incubated at 37 °C for 72 h, the percentage of DMSO in the medium never exceeded 0.25%. The number of living cells after 72 h of culture in the presence (or absence: control) of the various compounds is directly proportional to the intensity of the blue, which is quantitatively measured by a plate reader at 560 nm. The experiment was performed in quadruplicate and repeated 3 times.
Metabolism of 29h by DT-D
A 10 mM stock solution of 29h was prepared in DMSO and stock solutions of 4 mM NADH and 100 µM FAD were prepared in TRIS buffer pH 7.4. The enzyme 
Measurement of Intracellular ROS Generation
Intracellular ROS production was detected by using the peroxide-sensitive fluorescent probe DCF-DA. In brief, after treatment with 0, 0.25, 0. 
Western Blot Analysis
A549 and H596 cells were incubated in the presence of 29h, and after 48 h, were collected, centrifuged, and washed two times with ice cold PBS. The pellet was then re-suspended in lysis buffer. After the cells were lysed on ice for 20 min, lysates were centrifuged at 13000g at 4 °C for 15 min. The protein concentration in the supernatant was determined using the BCA protein assay reagents. Equal amounts of protein (20 µg) were resolved using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (8-12 % acrylamide gels) and transferred to PVDF Hybond-P membrane. Membranes were blocked for 1 h at room temperature. Membranes were then incubated with primary antibodies against caspase-3, caspase-8, caspase-9, Bax, Bcl-xl, cytochrome C, β-actin, the membrane being gently rotated overnight at 4°C.
The bound antibodies were detected using horseradish peroxidase (HRP)-conjugated second antibodies and visualized by the enhanced chemiluminescent reagent. 
In vivo tumor xenograft study
